Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
USRE49647E1 · kind E1 · reissue
0Cited by
0References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2020 |
| Grant date | Sep 12, 2023 |
| Priority date | — |
| Expiry date | Sep 23, 2040 |
Classification
- Technology area (CPC —)General
Abstract
Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.